Literature DB >> 16861963

Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.

Alena Skálová1, Douglas R Gnepp, Roderick H W Simpson, Jean E Lewis, Dirk Janssen, Radek Sima, Tomas Vanecek, Silvana Di Palma, Michal Michal.   

Abstract

Sclerosing polycystic adenosis (SPA) is a recently described, rare lesion of the salivary glands that bears a resemblance to epithelial proliferative lesions of the breast. The true nature of the lesion is unknown, but up to now it has been generally believed to represent a pseudoneoplastic sclerosing and inflammatory process. However, local recurrence developed in about one-third of the cases. Superimposed dysplastic changes ranging from low-grade dysplasia to carcinoma in situ were described in SPA. Although no metastases-related and/or disease-related patient deaths were documented, these clinical and histopathologic features raise the possibility that SPA might represent a neoplastic lesion. Polymorphism of the human androgen receptor locus is most frequently used to assess whether the pattern of X-chromosome inactivation is random or nonrandom, the latter strongly indicating clonality. In this study, the assay was applied to tissue from 12 examples of SPA. Three cases (males) were noninformative and 3 cases (females) could not be analyzed owing to poor quality of DNA, but all the remaining 6 lesions satisfied the criteria for monoclonality. We therefore conclude that the findings in the present study are further supporting evidence that SPA is a neoplasm, and not just a reactive process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861963     DOI: 10.1097/00000478-200608000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Sclerosing polycystic adenosis of the parotid gland: report of a bifocal, paucicystic variant with ductal carcinoma in situ and pronounced stromal distortion mimicking invasive carcinoma.

Authors:  Fredrik Petersson; Puay Hoon Tan; Jacqueline Siok-Gek Hwang
Journal:  Head Neck Pathol       Date:  2011-02-01

Review 2.  Sclerosing polycystic adenosis of salivary glands: a review with some emphasis on intraductal epithelial proliferations.

Authors:  Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2013-07-03

Review 3.  Newly described salivary gland tumors.

Authors:  Alena Skalova; Michal Michal; Roderick Hw Simpson
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

4.  What's new in the AFIP fascicle on salivary gland tumors: a few highlights from the 4th Series Atlas.

Authors:  Gary L Ellis
Journal:  Head Neck Pathol       Date:  2009-07-21

5.  Salivary gland tumor "wishes" to add to the next WHO Tumor Classification: sclerosing polycystic adenosis, mammary analogue secretory carcinoma, cribriform adenocarcinoma of the tongue and other sites, and mucinous variant of myoepithelioma.

Authors:  Douglas R Gnepp
Journal:  Head Neck Pathol       Date:  2014-03-05

6.  Intraductal carcinoma of salivary gland (so-called low-grade cribriform cystadenocarcinoma) arising in an intraparotid lymph node.

Authors:  Ilan Weinreb
Journal:  Head Neck Pathol       Date:  2011-03-26

7.  Sclerosing polycystic adenosis.

Authors:  Colin A Eliot; Alice B Smith; Robert D Foss
Journal:  Head Neck Pathol       Date:  2011-12-20

8.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland.

Authors:  Raja R Seethala; Göran Stenman
Journal:  Head Neck Pathol       Date:  2017-02-28

Review 9.  Sclerosing polycystic adenosis of the buccal mucosa.

Authors:  Shabnum Meer; Mario Altini
Journal:  Head Neck Pathol       Date:  2008-02-26

10.  Invasive carcinoma arising from sclerosing polycystic adenosis of the salivary gland.

Authors:  Rita Canas Marques; Ana Félix
Journal:  Virchows Arch       Date:  2014-03-02       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.